BREAKING: Cencora ($COR) inks $4.5B in acquisition loans and boosts revolver by $1.0B — revolver now $5.5B…
Filed with the SEC on · Summarized by InvestorsBot
BREAKING: Cencora ($COR) inks $4.5B in acquisition loans and boosts revolver by $1.0B — revolver now $5.5B 🚨💰 #Mergers #DebtMarkets #COR #OneOncology
ALERT: What this means — $COR’s $1.5B term loan + $3.0B 364‑day loan are earmarked to buy the majority of OneOncology; raises leverage and short‑term refinancing risk ⚠️📈 #M&A #Leverage #CreditRisk #OneOncology
Confirmed: Term loans = $1.5B (Tranche1 $500M 2‑yr, Tranche2 $1B 3‑yr). 364‑day facility = $3.0B. Rates = SOFR+ (75–125bps term; 87.5–112.5bps 364d). Ticking fees start 4/1/26. Bridge commitments reduced to $0 📝🏦 #DebtDeal #COR #FinTwit
ALERT: Next steps & shareholder impact — funding subject to Acquisition close; proceeds to pay purchase price, OneOncology debt & fees. Covenant: leverage ≤4.0x (can go to 4.5x for material deals) — may limit buybacks/dividends, pressure ratings 🔎📉 #Investing #COR #Credit